Damora Therapeutics (DMRA) vs Replimune Group (REPL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Replimune Group (REPL) has outperformed Damora Therapeutics (DMRA) over the past year, gaining 183.9% versus a gain of 12.9%. Over five years, REPL leads with a -56.2% price change compared with -76.3% for DMRA. Damora Therapeutics is the larger company by market cap ($1.25 billion vs $1.24 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMRA | REPL |
|---|---|---|
| Share price | $20.24 | $13.20 |
| Market cap | $1.25B | $1.24B |
| 1-day change | +3.53% | -0.38% |
| YTD return | -12.04% | +35.80% |
| 1-year return | +12.95% | +183.87% |
| 5-year return | -76.33% | -56.22% |
| EPS (TTM) | $-0.25 | $-3.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $38.33 | $16.33 |
| 52-week low | $4.95 | $1.50 |
| Distance from 52-week high | -47.19% | -19.17% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +131.67% | +47.73% |
| Average volume | 539.81K | 4.17M |
| Shares outstanding | 61.74M | 94.22M |
| Employees | 7 | 465 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- REPL has outperformed DMRA by 170.9 percentage points over the past year.
About Damora Therapeutics
DMRA stock →Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Replimune Group
REPL stock →Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 465 employees
DMRA vs REPL FAQ
Which is bigger, Damora Therapeutics or Replimune Group?
Damora Therapeutics (DMRA) is larger, with a market capitalization of $1.25B compared with $1.24B for Replimune Group (REPL).
Which stock has performed better over the past year, DMRA or REPL?
REPL returned +183.87% over the past 12 months, compared with +12.95% for DMRA (price return, excluding dividends). Past performance does not predict future results.
Are Damora Therapeutics and Replimune Group in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Damora Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Replimune Group.